Factbox: Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic

Sino Biopharmaceutical

06/06/2024 24:00

By Andrew Silver
       SHANGHAI, June 6 (Reuters) - At least 11 generic
versions of Novo Nordisk's  NOVOb.CO  popular diabetes drug
Ozempic are in the final stages of clinical trials in China, as
developers seek to profit from an early patent expiry of the
therapy's active ingredient semaglutide in China.    
    
    COMPANIES WHICH COMPLETED PHASE 3
    Hangzhou Jiuyuan Gene Engineering: It has said its drug has
"similar clinical efficacy and safety" as Ozempic  
    Livzon Pharmaceutical Group  000513.SZ   
    
    COMPANIES THAT FINISHED RECRUITING FOR PHASE 3 TRIALS
    Chongqing Chenan Biopharmaceutical/Shanghai Bovax
Biotechnology
    
    COMPANIES RECRUITING PARTICIPANTS FOR PHASE 3 TRIALS
    CSPC Pharmaceutical Group  1093.HK 
    Huadong Medicine  000963.SZ /Peg-Bio Biopharm 
    Sino Biopharmaceutical Limited  1177.HK  subsidiary
    Qilu Pharmaceutical

    COMPANIES THAT HAVE YET TO START RECRUITING
    Brilliant Pharmaceuticals 
    QL Biopharm 
    Sihuan Pharmaceutical  0460.HK  subsidiary
    United Laboratories  3933.HK  
    Source: records from http://www.chinadrugtrials.org.cn/ 

 (Reporting by Andrew Silver; Editing by Muralikumar
Anantharaman)
 ((andrew.silver@thomsonreuters.com;))